Journal article
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin
Abstract
Background: This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin in patients with advanced solid tumours, and to identify the maximum tolerated dose and the dose for use in future studies. Patients and methods: BAY 12-9566 and 5-fluorouracil/leucovorin were administered to 17 patients in 3 cohorts. Each patient …
Authors
Goel R; Chouinard E; Stewart DJ; Huan S; Hirte H; Stafford S; Waterfield B; Roach J; Lathia C; Agarwal V
Journal
Investigational New Drugs, Vol. 23, No. 1, pp. 63–71
Publisher
Springer Nature
Publication Date
January 2005
DOI
10.1023/b:drug.0000047107.35764.d9
ISSN
0167-6997
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Angiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsBiphenyl CompoundsCanadaCohort StudiesColorectal NeoplasmsDose-Response Relationship, DrugFemaleFluorouracilHumansKidney NeoplasmsLeucovorinLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMatrix Metalloproteinase InhibitorsMaximum Tolerated DoseOrganic ChemicalsPhenylbutyratesSafetySalvage Therapy